Skip to main content
Erschienen in: Journal of Clinical Immunology 5/2008

01.09.2008

Single Nucleotide Polymorphism in DNMT3B Promoter and the Risk for Idiopathic Thrombocytopenic Purpura in Chinese Population

verfasst von: Zhenping Chen, Zeping Zhou, Xiaoli Chen, Jianhui Xu, Aijuan Liu, Weiting Du, Dongsheng Gu, Jing Ge, Zhenxing Guo, Xiaoyan Wang, Xunwei Dong, Qian Ren, Renchi Yang

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

Epigenetic changes in gene expression, including DNA methylation and histone modifications, might contribute to autoimmunity. DNA methylation is mediated by a family of DNA methyltransferases. Polymorphisms of the DNA methyltransferase 3B (DNMT3B) gene may influence DNMT3B activity on DNA methylation, thereby modulating the susceptibility to some diseases. The purpose of this study was to investigate the association between the single nucleotide polymorphism (SNP) in promoter of the DNMT3B gene and the risk for development of idiopathic thrombocytopenic purpura (ITP).

Methods

In this hospital-based case-control study, the DNMT3B SNP was genotyped in 201 patients with ITP and 136 healthy controls by polymerase chain reaction-restriction fragment length polymorphism.

Results

The C/C genotype was not detected in both the patients with ITP and the controls. In the controls, the frequencies of T/T and C/T genotypes and T and C alleles were 97.8%, 2.2%, 98.9%, and 1.1%, respectively. There was no significant difference in genotype and allele distribution between the patients with ITP and the controls (P = 0.745 and 0.747, respectively). No significant difference was observed in genotype and allele distribution between the two groups when stratified by the age. The similar results were shown among the four groups of patients with ITP: acute childhood, chronic childhood, acute adult, and chronic adult.

Conclusion

This polymorphism was distributed similarly between the patients with ITP and the controls. It demonstrated that it may not be used as a stratification marker to predict the susceptibility to ITP, at least in the population of North China.
Literatur
1.
Zurück zum Zitat Yang R, Han ZC. Pathogenesis and management of chronic idiopathic thrombocytopenic purpura: an update. Int J Hematol. 2003;71:18–24. Yang R, Han ZC. Pathogenesis and management of chronic idiopathic thrombocytopenic purpura: an update. Int J Hematol. 2003;71:18–24.
2.
Zurück zum Zitat Zhou B, Zhao H, Yang RC, Han ZC. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol. 2005;54:107–16.PubMedCrossRef Zhou B, Zhao H, Yang RC, Han ZC. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol. 2005;54:107–16.PubMedCrossRef
3.
4.
5.
7.
Zurück zum Zitat Sanders VM. Epigenetic regulation of Th1 and Th2 cell development. Brain Behav Immun. 2006;20:317–24.PubMedCrossRef Sanders VM. Epigenetic regulation of Th1 and Th2 cell development. Brain Behav Immun. 2006;20:317–24.PubMedCrossRef
8.
Zurück zum Zitat Sekigawa I, Okada M, Ogasawara H, Kaneko H, Hishikawa T, Hashimoto H. DNA methylation in systemic lupus erythematosus. Lupus. 2003;12:79–85.PubMedCrossRef Sekigawa I, Okada M, Ogasawara H, Kaneko H, Hishikawa T, Hashimoto H. DNA methylation in systemic lupus erythematosus. Lupus. 2003;12:79–85.PubMedCrossRef
9.
Zurück zum Zitat Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol. 2006;176:7143–7.PubMed Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol. 2006;176:7143–7.PubMed
10.
11.
Zurück zum Zitat Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mrna expression of the human DNA methyltransferases (dnmts) 1, 3a and 3b during the g(0)/g(1) to s phase transition in normal and tumor cells. Nucleic Acids Res. 2000;28:2108–13.PubMedCrossRef Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mrna expression of the human DNA methyltransferases (dnmts) 1, 3a and 3b during the g(0)/g(1) to s phase transition in normal and tumor cells. Nucleic Acids Res. 2000;28:2108–13.PubMedCrossRef
12.
Zurück zum Zitat Liu K, Wang YF, Cantemir C, Muller MT. Endogenous assays of DNA methyltransferases: Evidence for differential activities of dnmt1, dnmt2, and dnmt3 in mammalian cells in vivo. Mol Cell Biol. 2003;23:2709–19.PubMedCrossRef Liu K, Wang YF, Cantemir C, Muller MT. Endogenous assays of DNA methyltransferases: Evidence for differential activities of dnmt1, dnmt2, and dnmt3 in mammalian cells in vivo. Mol Cell Biol. 2003;23:2709–19.PubMedCrossRef
13.
Zurück zum Zitat Klose RJ, Bird AP. Genomic DNA methylation: The mark and its mediators. Trends Biochem Sci. 2006;31:89–97.PubMedCrossRef Klose RJ, Bird AP. Genomic DNA methylation: The mark and its mediators. Trends Biochem Sci. 2006;31:89–97.PubMedCrossRef
14.
Zurück zum Zitat Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases dnmt3a and dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247–57.PubMedCrossRef Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases dnmt3a and dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247–57.PubMedCrossRef
15.
Zurück zum Zitat Chedin F, Lieber MR, Hsieh CL. The DNA methyltransferase-like protein dnmt3l stimulates de novo methylation by dnmt3a. Proc Natl Acad Sci U S A. 2002;99:16916–21.PubMedCrossRef Chedin F, Lieber MR, Hsieh CL. The DNA methyltransferase-like protein dnmt3l stimulates de novo methylation by dnmt3a. Proc Natl Acad Sci U S A. 2002;99:16916–21.PubMedCrossRef
16.
Zurück zum Zitat Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CM, et al. The dnmt3b DNA methyltransferase gene is mutated in the icf immunodeficiency syndrome. Proc Natl Acad Sci U S A. 1999;96:14412–7.PubMedCrossRef Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CM, et al. The dnmt3b DNA methyltransferase gene is mutated in the icf immunodeficiency syndrome. Proc Natl Acad Sci U S A. 1999;96:14412–7.PubMedCrossRef
17.
Zurück zum Zitat Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q. A novel polymorphism in human cytosine DNA-methyltransferase-3b promoter is associated with an increased risk of lung cancer. Cancer Res. 2002;62:4992–5.PubMed Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q. A novel polymorphism in human cytosine DNA-methyltransferase-3b promoter is associated with an increased risk of lung cancer. Cancer Res. 2002;62:4992–5.PubMed
18.
Zurück zum Zitat Wang L, Rodriguez M, Kim ES, Xu Y, Bekele N, El-Naggar AK, et al. A novel c/t polymorphism in the core promoter of human de novo cytosine DNA methyltransferase 3b6 is associated with prognosis in head and neck cancer. Int J Oncol. 2004;25:993–9.PubMed Wang L, Rodriguez M, Kim ES, Xu Y, Bekele N, El-Naggar AK, et al. A novel c/t polymorphism in the core promoter of human de novo cytosine DNA methyltransferase 3b6 is associated with prognosis in head and neck cancer. Int J Oncol. 2004;25:993–9.PubMed
19.
Zurück zum Zitat Lee SJ, Jeon HS, Jang JS, Park SH, Lee GY, Lee BH, et al. Dnmt3b polymorphisms and risk of primary lung cancer. Carcinogenesis. 2005;26:403–9.PubMedCrossRef Lee SJ, Jeon HS, Jang JS, Park SH, Lee GY, Lee BH, et al. Dnmt3b polymorphisms and risk of primary lung cancer. Carcinogenesis. 2005;26:403–9.PubMedCrossRef
20.
Zurück zum Zitat Wang T, Zhao H, Ren H, Guo J, Xu M, Yang R, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica. 2005;90:914–23.PubMed Wang T, Zhao H, Ren H, Guo J, Xu M, Yang R, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica. 2005;90:914–23.PubMed
21.
Zurück zum Zitat George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40.PubMed George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40.PubMed
22.
Zurück zum Zitat Zeller B, Rajantie J, Hedlund-Treutiger I, Tedgard U, Wesenberg F, Jonsson OG, et al. Childhood idiopathic thrombocytopenic purpura in the nordic countries: Epidemiology and predictors of chronic disease. Acta Paediatr. 2005;94:178–84.PubMedCrossRef Zeller B, Rajantie J, Hedlund-Treutiger I, Tedgard U, Wesenberg F, Jonsson OG, et al. Childhood idiopathic thrombocytopenic purpura in the nordic countries: Epidemiology and predictors of chronic disease. Acta Paediatr. 2005;94:178–84.PubMedCrossRef
23.
Zurück zum Zitat Zhao H, Li H, Zhang L, Wang T, Ji L, Yang R. Retrospective analysis of 472 chinese children with chronic idiopathic thrombocytopenic purpura: A single center experience. Haematologica. 2005;90:860–1.PubMed Zhao H, Li H, Zhang L, Wang T, Ji L, Yang R. Retrospective analysis of 472 chinese children with chronic idiopathic thrombocytopenic purpura: A single center experience. Haematologica. 2005;90:860–1.PubMed
24.
Zurück zum Zitat Chen X, Xu J, Chen Z, Zhou Z, Feng X, Zhou Y, et al. Interferon-gamma +874a/t and interleukin-4 intron3 vntr gene polymorphisms in Chinese patients with idiopathic thrombocytopenic purpura. Eur J Haematol. 2007;79:191–7.PubMedCrossRef Chen X, Xu J, Chen Z, Zhou Z, Feng X, Zhou Y, et al. Interferon-gamma +874a/t and interleukin-4 intron3 vntr gene polymorphisms in Chinese patients with idiopathic thrombocytopenic purpura. Eur J Haematol. 2007;79:191–7.PubMedCrossRef
25.
Zurück zum Zitat Ansel KM, Lee DU, Rao A. An epigenetic view of helper T cell differentiation. Nat Immunol. 2003;4:616–23.PubMedCrossRef Ansel KM, Lee DU, Rao A. An epigenetic view of helper T cell differentiation. Nat Immunol. 2003;4:616–23.PubMedCrossRef
26.
Zurück zum Zitat Reik W, Walter J. Evolution of imprinting mechanisms: The battle of the sexes begins in the zygote. Nat Genet. 2001;27:255–6.PubMedCrossRef Reik W, Walter J. Evolution of imprinting mechanisms: The battle of the sexes begins in the zygote. Nat Genet. 2001;27:255–6.PubMedCrossRef
27.
Zurück zum Zitat Richardson BC, Strahler JR, Pivirotto TS, Quddus J, Bayliss GE, Gross L, et al. Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum. 1992;35:47–62.PubMedCrossRef Richardson BC, Strahler JR, Pivirotto TS, Quddus J, Bayliss GE, Gross L, et al. Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum. 1992;35:47–62.PubMedCrossRef
28.
Zurück zum Zitat Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Baylin SB, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer. 1998;77:833–8.PubMedCrossRef Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Baylin SB, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer. 1998;77:833–8.PubMedCrossRef
29.
Zurück zum Zitat Richardson BC, Liebling MR, Hudson JL. Cd4+ cells treated with DNA methylation inhibitors induce autologous b cell differentiation. Clin Immunol Immunopathol. 1990;55:368–81.PubMedCrossRef Richardson BC, Liebling MR, Hudson JL. Cd4+ cells treated with DNA methylation inhibitors induce autologous b cell differentiation. Clin Immunol Immunopathol. 1990;55:368–81.PubMedCrossRef
30.
Zurück zum Zitat Deng C, Kaplan MJ, Yang J, Ray D, Zhang Z, McCune WJ, et al. Decreased ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum. 2001;44:397–407.PubMedCrossRef Deng C, Kaplan MJ, Yang J, Ray D, Zhang Z, McCune WJ, et al. Decreased ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum. 2001;44:397–407.PubMedCrossRef
31.
Zurück zum Zitat Montgomery KG, Liu MC, Eccles DM, Campbell IG. The dnmt3b C–>T promoter polymorphism and risk of breast cancer in a British population: A case-control study. Breast Cancer Res. 2004;6:R390–4.PubMedCrossRef Montgomery KG, Liu MC, Eccles DM, Campbell IG. The dnmt3b C–>T promoter polymorphism and risk of breast cancer in a British population: A case-control study. Breast Cancer Res. 2004;6:R390–4.PubMedCrossRef
Metadaten
Titel
Single Nucleotide Polymorphism in DNMT3B Promoter and the Risk for Idiopathic Thrombocytopenic Purpura in Chinese Population
verfasst von
Zhenping Chen
Zeping Zhou
Xiaoli Chen
Jianhui Xu
Aijuan Liu
Weiting Du
Dongsheng Gu
Jing Ge
Zhenxing Guo
Xiaoyan Wang
Xunwei Dong
Qian Ren
Renchi Yang
Publikationsdatum
01.09.2008
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 5/2008
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-008-9198-z

Weitere Artikel der Ausgabe 5/2008

Journal of Clinical Immunology 5/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.